Abstract
Immediate hypersensitivity reactions to betalactams are IgE mediated and constitute the most frequent allergic reactions mediated by specific immunological mechanisms. IgE responses to benzyl penicillin (BP), the first antibiotic producing the benzyl penicilloyl structure (BPO), are characterized by a quick release of inflammatory mediators, resulting in anaphylactic shock, urticaria and angioedema. With the progressive appearance of other structures, comprising cephalosporins, carbapenems, monobactams and clavulanic acid, IgE selective responses and cross-reactivity reactions were observed. The diagnosis of betalactam hypersensitivity, classically based on skin testing with major and minor determinants of benzyl penicillin or in vitro IgE antibodies to BP, has been modified by the inclusion of different determinants generated from these compounds, for which amoxicillin (AX) is the most relevant, followed by cephalosporins. Some subjects develop positive responses to several betalactams, mostly within the same family, but others develop a selective response. These are relevant for the appropriate selection of antimicrobial drugs in patients who have immediate hypersensitivity to betalactams.
Keywords: Betalactams, penicillins, amoxicillin, IgE, advances
Current Pharmaceutical Design
Title: Immediate Hypersensitivity Reactions to Penicillins and Other Betalactams
Volume: 12 Issue: 26
Author(s): C. Antunez, E. Martin, J. A. Cornejo-Garcia, N. Blanca-Lopez, R. R-Pena, C. Mayorga, M. J. Torres and M. Blanca
Affiliation:
Keywords: Betalactams, penicillins, amoxicillin, IgE, advances
Abstract: Immediate hypersensitivity reactions to betalactams are IgE mediated and constitute the most frequent allergic reactions mediated by specific immunological mechanisms. IgE responses to benzyl penicillin (BP), the first antibiotic producing the benzyl penicilloyl structure (BPO), are characterized by a quick release of inflammatory mediators, resulting in anaphylactic shock, urticaria and angioedema. With the progressive appearance of other structures, comprising cephalosporins, carbapenems, monobactams and clavulanic acid, IgE selective responses and cross-reactivity reactions were observed. The diagnosis of betalactam hypersensitivity, classically based on skin testing with major and minor determinants of benzyl penicillin or in vitro IgE antibodies to BP, has been modified by the inclusion of different determinants generated from these compounds, for which amoxicillin (AX) is the most relevant, followed by cephalosporins. Some subjects develop positive responses to several betalactams, mostly within the same family, but others develop a selective response. These are relevant for the appropriate selection of antimicrobial drugs in patients who have immediate hypersensitivity to betalactams.
Export Options
About this article
Cite this article as:
Antunez C., Martin E., Cornejo-Garcia A. J., Blanca-Lopez N., R-Pena R., Mayorga C., Torres J. M. and Blanca M., Immediate Hypersensitivity Reactions to Penicillins and Other Betalactams, Current Pharmaceutical Design 2006; 12 (26) . https://dx.doi.org/10.2174/138161206778194042
DOI https://dx.doi.org/10.2174/138161206778194042 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Allergic and Pseudoallergic Reactions Induced by Glucocorticoids: A Review
Current Pharmaceutical Design Parvalbumin as a Pleomorphic Protein
Current Protein & Peptide Science The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Insulin Therapy for Diabetes Epidemic: A Patent Review
Current Drug Delivery Management of Food-Induced Anaphylaxis: Unsolved Challenges
Current Clinical Pharmacology Clopidogrel Desensitization: Background and Recommendations for Use of a Rapid (4 Hour) Protocol
Current Vascular Pharmacology Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Pharmacogenomics in Aspirin Intolerance
Current Drug Metabolism Adverse Effects and Drug Interactions of Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Future of Angiotensin II Inhibition in Cardiovascular Medicine
Current Drug Targets - Cardiovascular & Hematological Disorders The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Hypersensitivity Reactions to Quinolones
Current Pharmaceutical Design Hypersensitivity Reactions to Non-Steroidal Anti-Inflammatory Drugs
Current Drug Metabolism Strategies for Leukotriene Modulation in Dermatology: Current Evidence and Visionary Perspectives
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Occupational Respiratory Pathology in Russia: Current Trends and Challenges
Current Respiratory Medicine Reviews Targeting Interleukin (IL) 5 for Asthma and Hypereosinophilic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Current Drug Safety Novel Possible Pharmaceutical Research Tools: Stem Cells, Gene Delivery and their Combination
Current Pharmaceutical Design Difficulties in Describing Allergic Disease Modulation by Pre-, Pro- and Synbiotics
Current Pharmaceutical Design